Despite gaining emergency use authorizations from the Food and Drug Administration (FDA) over a month ago, many doses of COVID-19 antibody treatments from Eli Lilly (NYSE: LLY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have gone unused. In this video from Motley Fool Live, recorded on Dec. 21, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the reasons for why the antibody drugs are being underutilized.
Why Aren’t Doctors Prescribing Eli Lilly’s and Regeneron’s COVID-19 Treatments?
Latest from Blog
Everyone wants a good deal in the stock market. But you won’t find undiscovered value in…
Apple (NASDAQ: AAPL), always trying to stay competitive in the cutthroat global smartphone market, is apparently…
If you’re tired of paying taxes on every dollar you earn, you need to explore the…
The NASDAQ-100 Technology Sector index comfortably outpaced the broader stock market’s returns in 2020. Apple (NASDAQ:…
Investors found some new reasons to like Procter & Gamble (NYSE: PG) stock in 2020. The…